Search

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.

MSK molecular geneticist and data scientist Elli Papaemmanuil is leading an initiative to identify the genomic changes that drive pediatric tumors.

New research from MSK investigates a promising approach against diabetic retinopathy and finds patients with early-onset colorectal cancer likely don’t need more frequent surveillance colonoscopies.

American tennis player and World No. 8 ranked James Blake will formally announce today the launch of the Thomas Blake, Sr., Memorial Research Fund, which he established to support cancer research at Memorial Sloan Kettering Cancer Center.

Brain cancer is deadly because it’s so difficult to study. Scientist Luis Parada has developed an innovative model to analyze how brain tumors form and respond to treatment.

Researchers have discovered a genetic mechanism that may trigger most childhood cancers.